Samsung Bioepis has become the second firm to receive a positive opinion recommending granting a pan-European marketing authorization for a biosimilar rival to Soliris (eculizumab) from the Committee for Medicinal Products for Human Use within the European Medicines Agency, after the firm’s Epysqli version today received a positive opinion from the CHMP.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?